The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients.
The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.
The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.
The share prices of 20 companies in the 360Dx Index rose last month, with Exact Sciences, Natera, Invitae, and NeoGenomics the biggest gainers.
The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.
Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.
The company agreed to settle a lawsuit alleging it improperly billed government health plans for its genetic tests.
The 360Dx Index was down 3 percent in February, reflecting similar losses in the broader markets. GenMark Diagnostics and Opko Health were the biggest decliners.
Leading the gainers in the 360 Index was GenMark, whose stock price was up 30 percent last month. Invitae led the decliners as its share price fell 24 percent.